Biotech Analyst Agrawal, along with Dr. Saidha, Neurology Professor at John Hopkins University, discuss TG Therapeutics’ Briumvi launch in Multiple Sclerosis on an Analyst/Industry conference call to be held on May 3 at 12 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TGTX:
- TG Therapeutics price target raised to $34 from $28 at H.C. Wainwright
- TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
- TG Therapeutics reports Q1 EPS (28c), consensus (37c)
- TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update
- TG Therapeutics announces issuance of permanent J-code for BRIUMVI